Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GLAGOV Imaging Study Of Amgen's Repatha Bodes Well For PCSK9 Class

Executive Summary

Positive results in GLAGOV lift PCSK9 inhibitor Repatha, but most likely are still not enough to get rid of reimbursement restrictions for the class, analysts say.

Advertisement

Related Content

Amgen's Repatha Emerges Unscathed In GLAGOV PCSK9 Imaging Study
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register